500660 Stock Overview
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally.
GlaxoSmithKline Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹1,738.15|
|52 Week High||₹1,917.00|
|52 Week Low||₹1,379.00|
|1 Month Change||-2.75%|
|3 Month Change||18.63%|
|1 Year Change||13.68%|
|3 Year Change||24.26%|
|5 Year Change||27.70%|
|Change since IPO||1,377.71%|
Recent News & Updates
|500660||IN Pharmaceuticals||IN Market|
Return vs Industry: 500660 exceeded the Indian Pharmaceuticals industry which returned 10.4% over the past year.
Return vs Market: 500660 underperformed the Indian Market which returned 36.2% over the past year.
|500660 Average Weekly Movement||4.8%|
|Pharmaceuticals Industry Average Movement||5.9%|
|Market Average Movement||6.7%|
|10% most volatile stocks in IN Market||9.8%|
|10% least volatile stocks in IN Market||4.1%|
Stable Share Price: 500660 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 500660's weekly volatility (5%) has been stable over the past year.
About the Company
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, gastrointestinal, nutrition, dermatology, respiratory, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Betnovate, Calpol, Ceftum, and Synflorix brands.
GlaxoSmithKline Pharmaceuticals Fundamentals Summary
|500660 fundamental statistics|
Is 500660 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|500660 income statement (TTM)|
|Cost of Revenue||₹14.23b|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||29.29|
|Net Profit Margin||14.30%|
How did 500660 perform over the long term?See historical performance and comparison
1.7%Current Dividend Yield
Is GlaxoSmithKline Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 500660 (₹1738.15) is trading above our estimate of fair value (₹469.29)
Significantly Below Fair Value: 500660 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 500660 is poor value based on its PE Ratio (59.3x) compared to the Indian Pharmaceuticals industry average (26x).
PE vs Market: 500660 is poor value based on its PE Ratio (59.3x) compared to the Indian market (23.5x).
Price to Earnings Growth Ratio
PEG Ratio: 500660 is poor value based on its PEG Ratio (4.1x)
Price to Book Ratio
PB vs Industry: 500660 is overvalued based on its PB Ratio (22.7x) compared to the IN Pharmaceuticals industry average (3.3x).
How is GlaxoSmithKline Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 500660's forecast earnings growth (14.5% per year) is above the savings rate (6.7%).
Earnings vs Market: 500660's earnings (14.5% per year) are forecast to grow slower than the Indian market (20.6% per year).
High Growth Earnings: 500660's earnings are forecast to grow, but not significantly.
Revenue vs Market: 500660's revenue (8.4% per year) is forecast to grow slower than the Indian market (12.7% per year).
High Growth Revenue: 500660's revenue (8.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 500660's Return on Equity is forecast to be high in 3 years time (34.1%)
How has GlaxoSmithKline Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 500660 has high quality earnings.
Growing Profit Margin: 500660 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: 500660's earnings have declined by 6.5% per year over the past 5 years.
Accelerating Growth: 500660 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 500660 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (29.7%).
Return on Equity
High ROE: 500660's Return on Equity (38.3%) is considered high.
How is GlaxoSmithKline Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: 500660's short term assets (₹21.8B) exceed its short term liabilities (₹14.8B).
Long Term Liabilities: 500660's short term assets (₹21.8B) exceed its long term liabilities (₹2.8B).
Debt to Equity History and Analysis
Debt Level: 500660 is debt free.
Reducing Debt: 500660 has no debt compared to 5 years ago when its debt to equity ratio was 0.09%.
Debt Coverage: 500660 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 500660 has no debt, therefore coverage of interest payments is not a concern.
What is GlaxoSmithKline Pharmaceuticals's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 500660's dividend (1.73%) is higher than the bottom 25% of dividend payers in the Indian market (0.3%).
High Dividend: 500660's dividend (1.73%) is in the top 25% of dividend payers in the Indian market (1.34%)
Stability and Growth of Payments
Stable Dividend: 500660's dividend payments have been volatile in the past 10 years.
Growing Dividend: 500660's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (102.5%), 500660's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 500660's dividends in 3 years are not forecast to be well covered by earnings (117.3% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Sridhar Venkatesh serves as Managing Director and Director at GlaxoSmithkline Pharmaceuticals Limited since April 1, 2020. Mr. Venkatesh served as the Commercial Head of Pharmaceuticals at GlaxoSmithkl...
CEO Compensation Analysis
Compensation vs Market: Sridhar's total compensation ($USD1.11M) is above average for companies of similar size in the Indian market ($USD571.56K).
Compensation vs Earnings: Insufficient data to compare Sridhar's compensation with company performance.
Experienced Management: 500660's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: 500660's board of directors are considered experienced (4.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
GlaxoSmithKline Pharmaceuticals Limited's employee growth, exchange listings and data sources
- Name: GlaxoSmithKline Pharmaceuticals Limited
- Ticker: 500660
- Exchange: BSE
- Founded: 1924
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹294.453b
- Shares outstanding: 169.41m
- Website: https://india-pharma.gsk.com
Number of Employees
- GlaxoSmithKline Pharmaceuticals Limited
- GSK House
- Dr. Annie Besant Road
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/17 16:16|
|End of Day Share Price||2022/01/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.